GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hubei Jumpcan Pharmaceutical Co 600566.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

29.40

+0.41%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥6.22bn

FY2016FY2025

Net income

CN¥1.78bn

FY2016FY2025

Free cash flow

CN¥1.10bn

FY2016FY2025

Shareholders' equity

CN¥14.61bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥6.22bnCN¥8.02bnCN¥9.65bnCN¥9.00bnCN¥7.63bnCN¥6.16bnCN¥6.94bnCN¥7.21bnCN¥5.64bnCN¥4.68bn
Gross profitCN¥4.91bnCN¥6.35bnCN¥7.87bnCN¥7.46bnCN¥6.35bnCN¥5.03bnCN¥5.83bnCN¥6.11bnCN¥4.79bnCN¥3.99bn
Research and developmentCN¥385.1mCN¥462.0mCN¥464.4mCN¥553.3mCN¥523.4mCN¥243.8mCN¥210.1mCN¥196.5mCN¥165.7mCN¥145.3m
Operating incomeCN¥1.88bnCN¥2.86bnCN¥3.26bnCN¥2.42bnCN¥1.93bnCN¥1.47bnCN¥1.86bnCN¥1.87bnCN¥1.37bnCN¥1.06bn
Net incomeCN¥1.78bnCN¥2.53bnCN¥2.82bnCN¥2.17bnCN¥1.72bnCN¥1.28bnCN¥1.62bnCN¥1.69bnCN¥1.22bnCN¥934.2m
Diluted earnings per share1.942.763.082.341.901.572.002.071.511.16

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥17.70bnCN¥18.46bnCN¥18.14bnCN¥14.98bnCN¥12.13bnCN¥10.52bnCN¥8.66bnCN¥7.80bnCN¥6.66bnCN¥4.99bn
Cash and short-term investments—CN¥11.83bnCN¥10.92bnCN¥7.86bnCN¥5.49bnCN¥4.22bnCN¥2.47bnCN¥1.59bnCN¥951.6mCN¥890.3m
Total liabilitiesCN¥3.07bnCN¥3.73bnCN¥4.77bnCN¥3.63bnCN¥3.00bnCN¥2.75bnCN¥2.56bnCN¥2.34bnCN¥2.26bnCN¥1.30bn
Debt—CN¥788.2mCN¥1.04bnCN¥400.6mCN¥630.1mCN¥603.8mCN¥576.8mCN¥552.6mCN¥697.9mCN¥84.9m
Shareholders' equityCN¥14.61bnCN¥14.70bnCN¥13.35bnCN¥11.34bnCN¥9.12bnCN¥7.76bnCN¥6.10bnCN¥5.46bnCN¥4.40bnCN¥3.66bn
Shares outstanding915m917m916m929m905m815m810m815m810m807m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥1.20bnCN¥2.18bnCN¥3.46bnCN¥2.62bnCN¥1.89bnCN¥1.78bnCN¥2.15bnCN¥1.71bnCN¥1.19bnCN¥913.1m
Capital spending−CN¥95.9m−CN¥174.3m−CN¥301.6m−CN¥243.7m−CN¥248.3m−CN¥429.6m−CN¥546.4m−CN¥668.1m−CN¥746.2m−CN¥323.5m
Free cash flowCN¥1.10bnCN¥2.00bnCN¥3.16bnCN¥2.38bnCN¥1.65bnCN¥1.35bnCN¥1.60bnCN¥1.04bnCN¥442.5mCN¥589.6m
Dividends paid−CN¥1.93bn−CN¥1.20bn−CN¥811.1m−CN¥604.0m−CN¥399.7m−CN¥1.00bn−CN¥1.00bn−CN¥810.7m−CN¥591.5m−CN¥547.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥1.12bnCN¥1.21bnCN¥2.29bnCN¥1.18bnCN¥1.22bnCN¥1.53bnCN¥2.21bnCN¥1.77bn
Gross profitCN¥858.8mCN¥991.7mCN¥1.91bnCN¥919.2mCN¥900.8mCN¥1.18bnCN¥1.75bnCN¥1.39bn
Operating incomeCN¥296.4mCN¥340.1mCN¥872.4mCN¥341.5mCN¥331.1mCN¥502.3mCN¥743.2mCN¥661.9m
Net incomeCN¥384.1mCN¥400.1mCN¥755.4mCN¥298.1mCN¥284.0mCN¥440.3mCN¥628.7mCN¥564.5m
Diluted earnings per share0.420.440.830.330.310.480.690.62
Cash from operations———−CN¥243.0mCN¥178.0mCN¥793.0m—CN¥187.0m
Capital spending−CN¥27.0m−CN¥193.0m−CN¥23.0m−CN¥31.0m−CN¥15.0m−CN¥25.0m−CN¥30.0m−CN¥36.0m
Free cash flow———−CN¥274.0mCN¥163.0mCN¥768.0m—CN¥151.0m
Total assetsCN¥17.01bnCN¥17.84bnCN¥17.70bnCN¥16.53bnCN¥16.68bnCN¥18.33bnCN¥18.46bnCN¥18.15bn
Cash and short-term investments———CN¥10.93bnCN¥10.93bnCN¥12.58bnCN¥11.83bnCN¥11.70bn
Debt—CN¥20.5m—CN¥749.6mCN¥531.8mCN¥627.0mCN¥787.1mCN¥1.18bn
Shareholders' equityCN¥13.79bnCN¥14.99bnCN¥14.61bnCN¥13.83bnCN¥13.50bnCN¥15.14bnCN¥14.70bnCN¥14.07bn

Financial ratios

Data as of 24 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Gross margin79.0%79.2%81.5%82.9%83.3%81.7%——
Operating margin30.2%35.7%33.7%26.9%25.3%23.8%——
Net margin28.6%31.6%29.2%24.1%22.5%20.7%——
Return on equity12.2%17.2%21.1%19.1%18.9%16.5%——
Return on assets10.0%13.7%15.6%14.5%14.2%12.1%——
Free cash flow yield5.8%10.5%16.8%12.6%9.7%11.1%——
Revenue growth-22.4%-17.0%7.3%17.9%23.8%-11.2%——
Earnings growth-29.8%-10.3%30.0%26.3%34.6%-21.3%——
Current ratio4.93x4.16x3.10x3.26x2.90x3.34x——
Debt to equity—0.05x0.08x0.04x—0.08x0.09x0.10x
Equity ratio82.5%79.6%73.6%75.7%75.2%73.8%——
Interest coverage163.99x104.97x185.29x77.59x54.47x43.73x——
R&D as a share of sales6.2%5.8%4.8%6.2%6.9%4.0%——
Buybacks as a share of market value0.3%-0.1%1.3%-2.6%-11.0%-0.6%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-11.6%0.2%5.1%
Operating income-8.2%5.0%9.5%
Net income-6.4%6.8%10.0%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin79.1%80.9%81.4%82.6%
Operating margin33.3%31.7%29.6%27.7%
Net margin30.3%28.3%26.3%24.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings13.510.510.211.714.912.912.116.225.227.0
Price to sales3.93.33.02.83.42.72.83.85.55.4

Dividends and splits

Per share, in the currency the company pays

Paid for 11 years. Last went ex-dividend on 30 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year1.742.091.300.880.680.451.231.23
  • 13-for-10 split · 18 May 2010
  • 1-to-1 reverse split · 12 Apr 2006

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.